Rosacea: Types, Triggers, Treatments & Skincare Rules

What Is Rosacea?

Rosacea is a chronic, relapsing inflammatory skin condition that predominantly affects the central face — the cheeks, nose, chin, and forehead. It typically emerges between ages 30 and 60, affects approximately 5% of adults worldwide (over 10% of light-skinned individuals), and follows a fluctuating course of flares and relative remissions. Women are diagnosed more often, but men tend to develop more severe presentations, including phymatous changes to the nose (rhinophyma).

Despite being one of the most common dermatological conditions seen in primary care, rosacea is frequently misdiagnosed as acne, eczema, or seborrheic dermatitis. The distinction matters because the wrong treatment — harsh exfoliants, retinoids applied carelessly, or stripping cleansers — can trigger a significant flare.

The Four Subtypes of Rosacea

Rosacea is classified into four subtypes that often coexist in the same patient. Understanding which subtype or combination you have determines the appropriate treatment approach.

Subtype 1 — Erythematotelangiectatic Rosacea (ETR)

The most common presentation: persistent central facial redness (erythema), visible dilated blood vessels (telangiectasia), frequent flushing, and burning or stinging sensations. The skin is typically dry, sensitive, and reactive to most topical products.

Subtype 2 — Papulopustular Rosacea (PPR)

Characterized by inflammatory papules and pustules — bumps that resemble acne but lack the comedones (blackheads and whiteheads) of acne vulgaris. The underlying persistent redness of subtype 1 is frequently present simultaneously. PPR is the form most often confused with adult-onset acne.

Subtype 3 — Phymatous Rosacea

Involves skin thickening, irregular surface nodularity, and enlargement of sebaceous glands. Rhinophyma — a bulbous, enlarged, red nose — is the classic manifestation, though phymatous changes can occur on the chin, forehead, cheeks, or ears. This subtype is significantly more common in men.

Subtype 4 — Ocular Rosacea

Eye involvement occurs in more than 50% of rosacea patients and may precede facial symptoms. Symptoms include dryness, grittiness, burning, foreign body sensation, light sensitivity (photophobia), redness of the eyes and eyelids (blepharitis), and in severe untreated cases, vision impairment from corneal involvement. Ocular rosacea warrants referral to an ophthalmologist.

Causes and Pathophysiology

Rosacea does not have a single cause — it emerges from the convergence of genetic susceptibility, immune dysregulation, microbial imbalance, and neurovascular dysfunction.

Dysregulated Innate Immunity

The most extensively characterized pathway involves toll-like receptor 2 (TLR2), kallikrein-5 (KLK5), and the antimicrobial peptide cathelicidin (LL-37). In rosacea-affected skin, overexpression of TLR2 leads to KLK5 converting the precursor hCAP18 into LL-37 at abnormally high levels. LL-37 then activates mast cells, promotes vascular permeability, triggers neurogenic inflammation, and sustains a chronic low-grade immune response. This positive-feedback loop is the core engine of rosacea's persistent redness and inflammation.

Demodex Mite Overgrowth

Demodex folliculorum and Demodex brevis are microscopic mites that inhabit hair follicles and sebaceous glands on all human faces. In rosacea patients, mite density is dramatically elevated — a meta-analysis found a 70.4% Demodex colonization rate in rosacea patients compared with 31.8% in healthy controls. These mites appear to activate the NLRP3 inflammasome via TLR2, amplifying the inflammatory cascade. The efficacy of ivermectin (an antiparasitic) as a rosacea treatment reflects the clinical relevance of this pathway.

Neurovascular Dysregulation

Rosacea skin shows elevated transient receptor potential (TRP) ion channels and elevated neuropeptides including substance P, CGRP, and PACAP — all of which promote vasodilation, mast cell activation, and the flushing that is so characteristic of the condition. The nervous and immune systems communicate bidirectionally in rosacea, sustaining neurogenic inflammation.

Skin Barrier Dysfunction

Rosacea patients exhibit reduced claudin expression (weakening tight junctions between skin cells), increased transepidermal water loss (TEWL), reduced stratum corneum hydration, and elevated skin pH. These barrier deficits allow environmental irritants deeper access and contribute to the hyperreactivity that characterizes rosacea-prone skin.

Genetic Predisposition

A twin study demonstrated that genetic factors account for approximately 46% of rosacea susceptibility, with environmental factors covering the rest. Genetic polymorphisms affect the immune, neural, and vascular systems — explaining why fair-skinned individuals of Celtic or Northern European ancestry are most commonly affected, though rosacea occurs in all skin types.

Common Triggers

Triggers are external or internal stimuli that temporarily amplify the rosacea pathways described above, producing a flare of redness, flushing, or pustulation. They are highly individual — what triggers one person may not affect another.

A National Rosacea Society survey of 1,066 patients identified the most common triggers:

Sun exposure is the leading trigger for most patients — UV radiation promotes reactive oxygen species (ROS) production and upregulates angiogenic factors that dilate facial vessels. Daily broad-spectrum SPF 30+ is the single most impactful preventive measure.

Alcohol, particularly red wine, causes direct vasodilation and gut microbiome disruption. Spicy foods activate TRP channels on nerve endings. Emotional stress engages the hypothalamic-pituitary-adrenal (HPA) axis, worsening barrier function and amplifying neurovascular reactivity.

Skincare products are an underappreciated trigger. Products containing alcohol, fragrance, menthol, camphor, glycolic acid, lactic acid, or sodium lauryl sulfate are among the most common culprits in product-triggered flares.

Diagnosis

Rosacea is a clinical diagnosis — no blood tests or biopsies are required for typical presentations. A dermatologist will assess:

• The distribution and nature of redness (central face, persistent, with or without visible vessels)
• The presence and type of lesions (papules and pustules without comedones distinguish PPR from acne)
• Eye symptoms and eyelid examination
• Skin thickening changes
• Symptom history and trigger patterns

If the diagnosis is uncertain — particularly if seborrheic dermatitis, lupus erythematosus, or perioral dermatitis is suspected — a skin biopsy can clarify the picture.

Treatment

There is no cure for rosacea. The goal of treatment is control: reducing flare frequency, managing inflammation, and preventing progression. Effective management almost always combines lifestyle measures, gentle skincare, and medical treatment.

Foundation: Trigger Avoidance and Sun Protection

Identifying and avoiding personal triggers is the most impactful long-term strategy. Keeping a symptom diary for 4–6 weeks — noting foods, activities, weather, and products — helps isolate the most significant individual triggers.

Daily broad-spectrum SPF 30+ sunscreen containing zinc oxide or titanium dioxide is the cornerstone of any rosacea care plan. Chemical sunscreens can irritate some patients; mineral formulations are better tolerated.

Gentle Skincare Fundamentals

The barrier dysfunction in rosacea makes gentle, non-irritating skincare essential:

• Cleanse twice daily with a mild, fragrance-free, pH-balanced cleanser applied with fingertips — no washcloths or scrubbing
• Apply a fragrance-free, ceramide-containing moisturizer to damp skin twice daily
• Avoid any product containing alcohol, camphor, menthol, glycolic acid, lactic acid, fragrance, or sodium lauryl sulfate

Topical Prescription Treatments

Azelaic acid (15% gel or 20% cream): FDA-approved for papulopustular rosacea. Acts via multiple mechanisms: reduces KLK5 and cathelicidin expression, inhibits ROS production, kills bacteria without promoting resistance, and reduces post-inflammatory hyperpigmentation. Comparative trials show superiority over metronidazole on some measures. Mild transient stinging on application in the first weeks is common.

Metronidazole (0.75% gel/cream or 1% cream): A long-standing first-line topical for PPR with well-established efficacy and an excellent safety profile. Anti-inflammatory and antiparasitic activity.

Ivermectin 1% cream (Soolantra): An antiparasitic that reduces Demodex mite density and has independent anti-inflammatory activity. A head-to-head trial against metronidazole demonstrated superior efficacy for ivermectin on inflammatory lesion count at 16 weeks.

Brimonidine 0.33% gel (Mirvaso): A selective alpha-2 adrenergic agonist that causes temporary vasoconstriction — reducing erythema and flushing within 30 minutes of application for up to 12 hours. Not a disease-modifying treatment; some patients experience rebound redness after the effect wanes.

Oxymetazoline 1% cream (Rhofade): An alpha-1 adrenergic agonist approved for persistent facial erythema of rosacea. Similar rapid-onset vascular effect to brimonidine.

Oral Treatments

Low-dose doxycycline (40 mg modified-release, twice daily): The first FDA-cleared oral treatment specifically for rosacea. At this sub-antibiotic dose, doxycycline is anti-inflammatory rather than antibiotic — it inhibits matrix metalloproteinases and chemotaxis without promoting antibiotic resistance. Used for moderate-to-severe PPR.

Conventional oral antibiotics (doxycycline 100 mg or minocycline): Prescribed for more severe inflammatory presentations. Courses are typically limited to 3 months, used alongside topical agents to reduce antibiotic resistance risk.

Oral isotretinoin (low dose): Reserved for severe, treatment-resistant rosacea — particularly phymatous subtypes. Acts partly by reducing sebaceous gland size and downregulating TLR2 expression. Requires dermatologist monitoring.

Beta-blockers (propranolol, carvedilol): Prescribed off-label for disabling flushing and vascular reactivity. Address both the vascular component and the anxiety that often exacerbates flushing.

Procedural and Laser Treatments

For persistent erythema and visible vessels that don't respond adequately to topical treatment:

• Pulsed dye laser (PDL) and KTP laser — target hemoglobin in dilated vessels, reducing telangiectasia and background redness
• Intense pulsed light (IPL) — broad-spectrum light therapy effective for diffuse redness and flushing; typically 3–5 sessions required
• Nd:YAG laser — suitable for deeper or larger vessels
• CO₂ or Erbium laser ablation — used for surgical reshaping in phymatous rosacea

Ocular Rosacea

Requires referral to an ophthalmologist. Warm compresses, lid hygiene with dilute baby shampoo, artificial tears, and topical cyclosporine eye drops are commonly prescribed. Severe cases may require oral doxycycline for both ocular and facial disease.

Myths About Rosacea

"Rosacea is caused by poor hygiene." False. Rosacea is an immune and neurovascular condition, not a cleanliness problem. Over-washing aggressively worsens barrier function and amplifies inflammation.

"Rosacea is just flushing — it will go away on its own." Untreated rosacea tends to progress. Repeated flushing episodes cause cumulative vascular dilation and can permanently worsen redness and telangiectasia over time.

"Only fair-skinned people get rosacea." Rosacea affects all skin tones. It is more prevalent in lighter skin, where redness is more visible — but it occurs in South Asian, East Asian, Middle Eastern, Hispanic, and Black patients, where it is frequently underdiagnosed because redness is less apparent.

"Rosacea will eventually clear up like teenage acne." Rosacea is a chronic condition. Without management, it typically worsens with age. With appropriate treatment, the majority of patients achieve excellent symptom control.

When to See a Dermatologist

Any persistent unexplained facial redness lasting more than a few weeks warrants evaluation. See a dermatologist promptly if:

• Persistent facial redness or visible blood vessels are present on the central face
• Acne-like bumps and pustules appear without blackheads or whiteheads
• Flushing is frequent, intense, and disruptive to quality of life
• The eyes feel gritty, dry, or burning — or eyelids are chronically red (ocular rosacea can damage vision if untreated)
• The nose, chin, or cheeks appear to be thickening
• OTC treatments have been tried for 8–12 weeks without improvement
• Rosacea is affecting mental health, social functioning, or confidence

Early diagnosis and treatment substantially reduce the risk of progressive skin changes. Rosacea is highly manageable when treated correctly — the earlier a plan is in place, the better the long-term outcome.